FDA code for non-replicate crossover? [Software]

posted by d_labes  – Berlin, Germany, 2014-02-03 16:54 (4096 d 06:21 ago) – Posting: # 12324
Views: 27,788

Dear Helmut,

❝ ... But – hey! – that’s not the code given in FDA’s guidances. ;-)


where does your opinion came from?
So far as I know there is no code given in the FDA's guidances for non-replicate cross-over studies.

Moreover on page 10 of the 2001 Statistical guidance they recommend Proc GLM:
"General linear model procedures available in PROC GLM in SAS or equivalent software are preferred, although linear mixed-effects model procedures can also be indicated for analysis of nonreplicated crossover studies.

For example, for a conventional two-treatment, two-period, two-sequence (2 x 2) randomized crossover design, the statistical model typically includes factors accounting for the following sources of variation: sequence, subjects nested in sequences, period, and treatment. The Estimate statement in SAS PROC GLM, or equivalent statement in other software, should be used to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences."

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,670 registered users;
25 visitors (0 registered, 25 guests [including 6 identified bots]).
Forum time: 00:16 CEST (Europe/Vienna)

The true Enlightenment thinker, the true rationalist,
never wants to talk anyone into anything.
No, he does not even want to convince;
all the time he is aware that he may be wrong.    Karl R. Popper

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5